Wells Fargo & Company MN raised its position in AVROBIO, Inc. (NASDAQ:AVRO) by 267.7% in the fourth quarter, HoldingsChannel reports. The fund owned 78,390 shares of the company’s stock after purchasing an additional 57,072 shares during the quarter. Wells Fargo & Company MN’s holdings in AVROBIO were worth $1,093,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AVRO. Great West Life Assurance Co. Can lifted its holdings in shares of AVROBIO by 810.7% in the 3rd quarter. Great West Life Assurance Co. Can now owns 12,986 shares of the company’s stock worth $31,000 after purchasing an additional 11,560 shares in the last quarter. Jane Street Group LLC bought a new stake in AVROBIO during the 3rd quarter valued at $132,000. Arizona State Retirement System acquired a new position in AVROBIO during the fourth quarter worth $142,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of AVROBIO by 7.0% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,289 shares of the company’s stock valued at $185,000 after buying an additional 871 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new position in shares of AVROBIO during the fourth quarter valued at about $186,000. Hedge funds and other institutional investors own 86.71% of the company’s stock.
A number of analysts have commented on the company. Zacks Investment Research raised AVROBIO from a “sell” rating to a “hold” rating in a report on Thursday, January 28th. Stifel Nicolaus started coverage on AVROBIO in a research report on Monday, March 8th. They issued a “hold” rating and a $14.00 price target for the company. SVB Leerink restated a “hold” rating and set a $18.00 price target on shares of AVROBIO in a report on Sunday, March 21st. Finally, Barclays assumed coverage on shares of AVROBIO in a research note on Monday, March 15th. They issued an “overweight” rating and a $23.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $25.22.
AVROBIO (NASDAQ:AVRO) last announced its quarterly earnings data on Wednesday, March 17th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.17. Analysts forecast that AVROBIO, Inc. will post -3.45 EPS for the current year.
AVROBIO Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.
Want to see what other hedge funds are holding AVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVROBIO, Inc. (NASDAQ:AVRO).
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.